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Ureteral strictures arising from radiotherapy for the treatment of prostate cancer are rare. We describe
four cases of these ureteral strictures emphasizing pre-operative factors that may have contributed to
development of the strictures, their ultimate surgical management, and the patients’ short-term
outcomes.
 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
In the United States there are around 3 million survivors of
prostate cancer.1 Deﬁnitive radiotherapy (XRT) treatment of local-
ized prostate cancer is used in approximately 37% of newly diag-
nosed men.2 Severe urinary adverse events (AEs) are rare and some
estimates are as low as 0.1%.3 AEs are increased with combined
modality treatment, e.g. radical prostatectomy (RP) with XRT.4
Urethral obstruction is the most common severe AE, but obstruc-
tion can also occur within the pelvic ureter.4
Jarosek et al analyzed Surveillance, Epidemiology and End
Results (SEER)-Medicare data to examine long-term AEs of XRT for
prostate cancer. They found that ureteral stricture was an uncom-
mon high-grade AE, with a 10 year propensity-weighted cumula-
tive incidence of only 2.7% in men treated with RP and external
beam radiotherapy (EBRT) compared to 1.2% in controls.4 The
authors, however, were unable to describe management of this AE
with the limitations of SEER-Medicare analysis.ent of Surgery Genitourinary
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Inc. This is an open access article uUnderstanding AEs associated with XRT used to treat prostate
cancer is essential for counseling patients and alerts urologists to
monitor for rare AEs like ureteral stricture. We undertook this study
in order to describe how these ureteral strictures were managed
surgically. We hypothesized that urinary tract reconstruction was
feasible in these cases.Case presentation
Patient characteristics
We identiﬁed 4 men from our prospective database of 80 men
with high-grade AEs from XRT for the treatment of prostate cancer.
All of the patients were treated with combined modality therapy
consisting of salvage EBRT after RP in 3 cases and high-dose-rate
brachytherapy and EBRT in the remaining case. Mean latency
period between XRT and ureteral stricture was 2.75 years (range 1e
6 years). Three patients had urolithiasis, requiring ureteroscopy,
which preceded clinically evident ureteral stricture. The mean age
and Charlson Comorbidity Index was 72.8 (range 64e79) and 4.8
(range 4e6), respectively. At the time of diagnosis with ureteral
stricture, mean serum creatinine was 2.2 mg/dL, glomerular ﬁltra-
tion rate (GFR) was 38.3 mL/min and all men had no evidence of
prostate cancer (Table 1).nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Patient characteristics
Variable Mean Range
Age (years) 72.8 68e74
Charlson comorbidity index 4.75 4e7
XRT treatment (n) RP þ EBRT ¼ 3
HDR þ EBRT ¼ 1
Time from XRT (years) 2.75 1e6
Stricture length (cm) 7 2e13
Hospital stay (days) 4 3e5
GFR improvement after surgery (mL/min) 6 4e7
Creatinine improvement after surgery (mg/dL) 0.29 0.1e0.4
XRT (radiation therapy), RP (radical prostatectomy), EBRT (external beam radio-
therapy), HDR (high-dose-rate brachytherapy).
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and bilateral in 1, and the strictures were all within the pelvis
(Fig. 1). The mean stricture length was 7 cm (range 2e13 cm).
Patients had attempts at endoscopic management in all cases with
an average of 3.5 procedures prior to surgical management. One
patient was temporized with a stent, two with percutaneous
nephrostomy tubes, and one did not have kidney drainage prior to
surgery. Nuclear medicine MAG-3 renogramwas performed on the
3 patients with unilateral obstruction and showed a mean function
of 22% (range 12e28) prior to surgery.Management
All patients underwent hyperbaric oxygen therapy, either before
or after ureteral reconstruction. Three patients with unilateral
strictures had a ureteral re-implantation; 2 with a Boari ﬂap and 1
with a psoas hitch. The patient with bilateral ureteral strictures
required bilateral ileal ureteral substitution. Omental ﬂaps were
used in all of the cases to either wrap the anastomosis of the ureter
or ileal limb with the bladder. The mean hospital stay was 4 days
(range 3e5). There were no peri-operative complications within 6
weeks of surgery.Figure 1. Pre-operative retrograde ureteropyelograms showing relatively short stric-
ture of the distal ureter (A) versus pelvic obliteration of the lower ureter (B).Follow up
The median follow up was 5 months (range 3e12 months). Pa-
tients had a post-operative cystogram at 4 weeks (Fig. 2) prior to
ureteral stent and Foley catheter removal. Long-term follow up
imaging consisted of renal ultrasound in all 4 patients, which
showed resolved hydronephrosis in all patients. The mean
improvement of serum creatinine after surgery was 0.29 mg/dL and
GFR was 6 mL/min. Improved or stable renal function was noted in
all patients. None of the patients has had recurrent ureteral
stricture.Discussion
There is little data about the treatment of ureteral strictures
arising from XRT for prostate cancer. The condition is low risk ac-
cording to SEER-Medicare analysis,4 however, in our prospective
patient registry of menwith high-grade urologic complications post
XRT, the incidence was 5%.
Ureteral strictures are often managed with stenting and peri-
odic stent exchanges. In our series, 2 of the patients could not
have stents placed, because the scarring of the ureter was too
severe and 1 had persistent asymptomatic hydronephrosis with a
stent.In our cases, all of the men had combined modality therapy and
3 out of 4 men had EBRT for salvage therapy after RP. Similar to
these ﬁndings, Jarosek et al found that ureteral strictures weremost
common in patients who received RPþ EBRT. Anatomically, after RP
the ureters are pulled medially and the bladder neck inferiorly, and
it has been hypothesized that this is the mechanism for ureteral
obstruction with subsequent EBRT.5 Interestingly 75% of our pa-
tients had ureteroscopy for ureteral stones, prior to developing
signiﬁcant ureteral stenosis. One could propose a two hit
hypothesis to explain the development of stricture in these men;
Figure 2. Post-operative cystogram showing Boari Flap reconstruction (A), and crea-
tion of a Y-type bilateral ileal ureter (B).
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tionally, the ureteral stones could be an indicator of sub-clinical
ureteral narrowing and surgeons should be aware of possible
further surgical trauma that might lead to complete obstruction.
All of the men in our series were reconstructed with the aid of
omental ﬂaps, and had hyperbaric oxygen treatments peri-
operatively. Omental ﬂaps provide two-fold beneﬁt in the recon-
structed radiated pelvis: (1) to augment blood ﬂowand (2) help seal
radiated anastomoses. Hyperbaric oxygen may theoretically
improve tissue quality in marginal areas of collateral radiation
damage and aid in healing, improving outcomes.
There are limitations to this study. The sample size of four pa-
tients limits our comments to observational. In addition, the limited
median follow up of 5 months is too short to comment about long-
term outcomes.Conclusion
Ureteral strictures caused by pelvic radiation are more common
in patients who have been treated with RP and subsequent salvage
EBRT. These strictures appear to be high risk when patients have
ureteral manipulation after XRT and urologists should avoid this if
possible. Patients may have limited recovery of their kidney func-
tion, however, the need for indwelling stents or percutaneous
nephrostomy drainage is eliminated with successful ureteral
reconstruction.Conﬂicts of interest
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